Mineralys Therapeutics Aktie News

Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Garth Russell – LifeSci Advisors Jon Congleton – Chief Executive Officer Adam Levy – Chief Financial Officer David Rodman – Chief Medical Officer Conference Call Participants Jack Padovano – Stifel Seamus Fernandez – Guggenheim Securities Michael DiFiore – Evercore Rami Katkh...

– Advance-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in Q4 2024 –

RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Bank of America Securities Health Care Conf...

RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2024, before the financial mark...

What To Buy After You Sell The Russell 2000

Mineralys Therapeutics, Inc. (MLYS) Q4 2023 Earnings Call Transcript

– Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in Q4 2024 a nd Launch-HTN trial in 2H 2025 –

RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2023...